Evidence map›Paper›PMID 39368995›Full record

ArticleCell death & disease2024

CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation.

Junfan Pan, Sixuan Wu, Qihong Pan, Yuan Zhang, Liu He, Qiwei Yao, Jinyuan Chen, Jiancheng Li, Yiquan Xu

Erratum issuedAbstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Junfan Pan *Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Sixuan Wu *Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Qihong Pan *Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Yuan Zhang *The First Affiliated Hospital of Xiamen University, Xiamen, China.
Liu HeSchool of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Qiwei YaoClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. yqwviva@126.com.ORCID 0000-0002-0156-046X
Jinyuan ChenThe Central Laboratory, Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. cjyfjmu@163.com.ORCID 0000-0002-0355-9892
Jiancheng LiClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. jianchengli_jack@126.com.ORCID 0000-0003-3686-9958
Yiquan XuClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. xuyiquan1018@fjmu.edu.cn.ORCID 0000-0003-4189-9692

Funding

Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation) 2021J05084
6 · The paper itself

Abstract

Patients with lung adenocarcinoma (LUAD) generally have poor prognosis. Abnormal cellular energy metabolism is a hallmark of LUAD. Glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1) is a member of the γ-glutamylcyclotransferase family and an unfolded protein response pathway regulatory gene. Its biological function and molecular regulatory mechanism, especially regarding energy metabolism underlying LUAD, remain unclear. By utilizing tissue microarray and data from The Cancer Genome Atlas and Gene Expression Omnibus, we found that CHAC1 expression was markedly higher in LUAD tissues than in non-tumor tissues, and was positively correlated with poor prognosis. Phenotypically, CHAC1 overexpression enhanced the proliferation, migration, invasion, tumor sphere formation, and glycolysis ability of LUAD cells, resulting in tumor growth both in vitro and in vivo. Mechanistically, through a shotgun mass spectrometry-based proteomic approach and high-throughput RNA sequencing, we found that CHAC1 acted as a bridge connecting UBA2 and PKM2, enhancing the SUMOylation of PKM2. The SUMOylated PKM2 then transferred from the cytoplasm to the nucleus, activating the expression of glycolysis-related genes and enhancing the Warburg effect. Lastly, E2F Transcription Factor 1 potently activated CHAC1 transcription by directly binding to the CHAC1 promoter in LUAD cells. The results of this study implied that CHAC1 regulates energy metabolism and promotes glycolysis in LUAD progression.

Indexed as

Adenocarcinoma of LungCarrier ProteinsGlucoseLung NeoplasmsMembrane ProteinsThyroid Hormone-Binding ProteinsThyroid HormonesAnimalsCell Line, TumorCell MovementCell NucleusCell ProliferationDisease ProgressionFemalegamma-GlutamylcyclotransferaseGene Expression Regulation, NeoplasticCarrier Proteinsgamma-GlutamylcyclotransferaseGlucoseMembrane ProteinsThyroid Hormone-Binding ProteinsThyroid Hormones

Identifiers

PMID39368995
PMCPMC11455913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.